NBRV Nabriva Therapeutics plc

2.4
-0.01  -0%
Previous Close 2.41
Open 2.4
Price To Book 2.89
Market Cap 192,038,189
Shares 80,015,912
Volume 42,605
Short Ratio
Av. Daily Volume 730,286

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review August 19, 2019.
Lefamulin - Intravenous and Oral
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
CRL issued April 30, 2019.
Contepo
Complicated urinary tract infections (cUTI)

Latest News

  1. SHAREHOLDER DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses to Contact the Firm
  2. FINAL DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Nabriva Therapeutics plc Investors of Important Deadline Today in the Securities Class Action – NBRV
  3. FINAL DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019
  4. MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  5. FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses to Contact the Firm
  6. DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019
  7. MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  8. DEADLINE ALERT - (NBRV) Nabriva Therapeutics PLC Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019
  9. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nabriva Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – NBRV
  10. 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses to Contact the Firm
  11. TOP RANKED ROSEN LAW FIRM: Announces Securities Class Action Lawsuit Against Nabriva Therapeutics plc; IMPORTANT JULY 8 DEADLINE - NBRV
  12. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nabriva Therapeutics, Equity Bancshares, Revlon and AAC Holdings and Encourages Investors to Contact the Firm
  13. JULY 8 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm
  14. NBRV: Zhang Investor Law Reminds Investors of July 8 Deadline in Securities Class Action Lawsuit Nabriva Therapeutics plc – NBRV
  15. DEADLINE ALERT - Nabriva Therapeutics PLC (NBRV) Bronstein, Gewirtz & Grossman, LLC Reminds Investors with Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: July 8, 2019
  16. 7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. X-Biotix Therapeutics Joins Antimicrobials Working Group
  18. FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm